View Post

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

In Clinical Studies News by Barbara Jacoby

Source: Translational Research in Oncology From: finance.yahoo.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided encouraging results and supported continuation …

View Post

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575)

In Clinical Studies News by Barbara Jacoby

Source: Ascentage Pharma From: prnewswire.com Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational New Drug (IND) application for the company’s novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been cleared by the US Food and Drug Administration (FDA) and the company is …

View Post

Neratinib Improve OS and CNS-Related Outcomes in Early-Stage HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Treatment with neratinib demonstrated a modest overall survival benefit in patients with HER2-positive breast cancer compared with placebo, according to the long-term OS and central nervous system results from the phase 3 ExteNET trial Treatment with the irreversible pan-HER inhibitor neratinib (Nerlynx) demonstrated a modest overall survival (OS) benefit in patients with HER2-positive breast cancer …

View Post

University of Miami looking for volunteers in breast cancer vaccine study

In In The News by Barbara Jacoby

From: winknews.com The University of Miami is looking for women willing to enroll in its clinical trial for a study on preventing the recurrence of triple negative breast cancer. That form of the cancer has limited treatment options and is likely to come back. The study hopes a vaccine can train the immune system to kill cancerous cells before they …

View Post

SBRT Safe for Cancer Patients With Multiple Metastases

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com Late adverse events in phase I trial indicate need for extended follow-up Stereotactic body radiotherapy (SBRT) proved safe for treating cancer patients with multiple metastases, according to a phase I trial. In the NRG-BR001 trial, standard doses of SBRT were safe in 35 patients with oligometastatic breast, prostate, and non-small cell lung cancer (NSCLC) with …

View Post

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

In Clinical Studies News by Barbara Jacoby

Source: Translational Research In Oncology From: globenewswire.com Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally. Rapid enrollment of this randomized, …

View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …

View Post

Veru touts novel breast cancer treatment strategy as drug nears phase 3

In Clinical Studies News by Barbara Jacoby

By: Angus Liu From: fiercebiotech.com Hormone therapies, or endocrine therapies, are widely used to treat breast cancer that is estrogen receptor (ER)-positive, but resistance is a common problem. That has sparked interest in drugs targeting the androgen receptor (AR). But the role of AR in ER-positive disease remains unclear, leading to the development of both AR agonists and antagonists. Now …

View Post

Changing the doses to treat aggressive breast cancer

In In The News by Barbara Jacoby

By: Jim Mertens From: wqad.com Is it possible to get the benefits of chemo without the side effects? Researchers are looking into a new treatment for an aggressive form of breast cancer that is showing some promise. Almost 300,000 American women will hear the words, “You have breast cancer” this year alone. One in four of those breast cancer diagnosis …

View Post

PET Imaging Reveals Which Breast Cancer Patients Won’t Respond to Hormone Therapy

In Clinical Studies News by Barbara Jacoby

By: Whitney J. Palmer From: diagnosticimaging.com Hormone therapy is only effective in roughly half of estrogen receptor-positive cancers. Being able to identify patients that will not respond could save valuable treatment time. The answer to whether hormone replacement therapy will work for a woman with breast cancer likely comes down to whether her estrogen receptors are working – a function …